Trial Profile
Phase II Trial of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Adenocarcinoma of the Prostate.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Bicalutamide; Leuprorelin
- Indications Prostate cancer
- Focus Therapeutic Use
- 30 Jan 2009 Planned patient numbers amended from 40 to 14 as reported by ClinicalTrials.gov.
- 30 Jan 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 30 Jan 2009 Planned end date changed from 1 Mar 2010 to 1 Oct 2008 as reported by ClinicalTrials.gov.